Black Diamond Therapeutics, Inc. (BDTX) Stock

Black Diamond Therapeutics, Inc. (BDTX) is a Healthcare stock trading at $1.65 (as of 2026-06-18), with a market capitalization of $120.33M and a trailing P/E of -2.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Black Diamond Therapeutics, Inc. is a biotechnology company that discovers, develops, and commercializes medicines targeting genetically defined tumors. Its pipeline includes small-molecule inhibitors for specific oncogenic EGFR/HER2 and BRAF alterations, including brain-penetrant candidates, which are intended for use in patients with these tumor-driving mutations.

Valuation — source: SEC EDGAR (first-party)
Price$1.65
Market Cap$120.33M
P/E Ratio-2.3
EV / EBITDA-1.3
Price / Book0.96
DCF Value (model)$9.18
DCF Upside vs Price456.4%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$70.00M
Net Margin32.0%
Return on Equity-41.4%
Current Ratio8.46
Financial Health — source: SEC EDGAR
Altman Z-Score-0.95 (distress)
Valuation vs Sector & Industry
Stock P/E-2.3
Sector P/E (Healthcare)20.9
Industry P/E (Pharmaceutical Products)17.0
vs Sector-111.2%
vs Industry-113.7%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderT. Rowe Price Investment Management, Inc. ($22.50M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOMark A. Velleca
Employees24
CountryUS
IPO Date2020-01-31

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Corbus Pharmaceuticals Holdings, Inc. (CRBP)
  • Alpha Cognition Inc. Common Stock (ACOG)
  • Seres Therapeutics, Inc. (MCRB)
  • Actuate Therapeutics Inc (ACTU)
  • Elicio Therapeutics, Inc. (ELTX)
  • Opus Genetics, Inc. (IRD)
  • Anixa Biosciences, Inc. (ANIX)
  • Context Therapeutics Inc. (CNTX)
BDTX earnings history · BDTX institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.